Analysen von Graham Parry
| 06.12.17 | Novartis Underperform | Merrill Lynch & Co., Inc. | |
| 20.05.15 | GSK Underperform | Merrill Lynch & Co., Inc. | |
| 09.12.14 | GSK Underperform | Merrill Lynch & Co., Inc. |
| 06.12.17 | Novartis Underperform | Merrill Lynch & Co., Inc. | |
| 20.05.15 | GSK Underperform | Merrill Lynch & Co., Inc. | |
| 09.12.14 | GSK Underperform | Merrill Lynch & Co., Inc. |